ICCC · Immucell Corp /De/
Market Cap
$89.46M
Shares
9.08M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$9.85
Open$9.91
Day$9.63–9.91
52W close$4.56–11.72
Avg vol 30d26K
Short int19K · 0.2% float · 1.0d
Short vol18%
Last earningsAug 14, 2026
DataJan 2020–Sep 2026
Filing10-Q · Aug 13
Up next
Next earnings call
Nov 15, 2026
Est · unconfirmed
· in 9 wks
filed Aug 13, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$30.68M
Trailing 12 months
Net income (TTM)
$787,373
Trailing 12 months
Revenue growth YoY
+11.5%
Year over year
Operating margin
12.6%
Trailing 12 months
P / E (TTM)
141.6
Trailing earnings · reciprocal yield 0.7%
FCF yield
4.7%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+1.7%
Year over year · more shares
Price change (1Y)
+61.0%
Trailing year
Short interest
0.2%
Latest settlement · 1.0 days to cover
Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Neutral
Momentum
Strong
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
High
Market backdrop
VIX 15.8 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+21%
above
Price vs 50-day avg
−7%
below
RSI (14)
41
neutral
MACD trend
Positive
52-week position
74%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−10%
trailing
6-month return
+62%
trailing
YTD return
+60%
this year
Relative strength
+44%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $11 › 200d $8 — 50d above 200d
Institutional flow
Accumulating
+15% holders QoQ · +7 funds added
Insider flow
Accumulating
Net +$76.0K over 90 days · 0% sells
Short interest
Rising
0.21% of float · ▲ +26.6% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
31 holders — mid 3-yr range
Squeeze score
33
low risk · 0–100
Fundamentals
Revenue growth
+52%
Y/Y
Gross margin
43%
contracting
EPS growth
+54%
Y/Y
Free cash flow
$1.2M
Valuation
P/E 140.7
rich
Balance sheet
$5.3M
net debt
Quant / Vol
risk profile
Volatility
51%
annualized · 1-yr
Max drawdown
−33%
past year
ATR
3.5%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the Earnings Call filed Feb 23, 2021
quarterly
Current production capacity
$4.1M
annual
Current annual production capacity
$16.5M
Expanded annual production capacity
$23M
Prior guidance
period ended
· from the Earnings Call filed Feb 23, 2021
Net cash provided by operating activities (year-over-year increa
· year ended December 31, 2020
$1.1M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+21%
Bullish
Price vs 50-day avg
−7%
Bearish
RSI (14)
41
Neutral
MACD trend
Positive
Bullish
52-week position
74%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $11 › 200d $8 — 50d above 200d
Institutional flow
Accumulating
+15% holders QoQ · +7 funds added
Insider flow
Accumulating
Net +$76.0K over 90 days · 0% sells
Short interest
Rising
0.21% of float · ▲ +26.6% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
31 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $5
Now $10 · 74%
Range high $12
vs 200-day avg +21%
vs 50-day avg -7%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ICCC
this stock
Immucell Corp /De/
|
$89.46M | +60.2% | +51.6% | 140.7 | 0.2% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$130.64B | +13.7% | +46.2% | 30.0 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$80.46B | +1.2% | +20.8% | 19.4 | 2.5% |
|
ARGX
Argenx SE
|
$61.22B | +17.1% | — | — | 2.0% |
|
MRNA
Moderna, Inc.
|
$57.48B | +388.2% | +4.3% | — | 9.8% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ICCC | -1.5% | -9.6% | +62.3% | +0.6% | +60.2% |
| SPY | -1.2% | -1.8% | +17.8% | -0.4% | +12.1% |
| vs SPY | -0.4% | -7.9% | +44.4% | +1.0% | +48.1% |